REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Annual Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2024-12-31

Swipe to see the full flow
REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Annual Balance SheetBalance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.Current liabilities$3.94 BLiabilities$8.41 BCurrent assets$18.66 BNon-current liabilities$4.46 BAssets$37.76 BEquity$29.35 BGross equity(calculated)$44.53 BNon-current assets$19.10 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable securitiesAccounts receivable, netInventoriesCash and cash equivalentsPrepaid expenses and other current assetsMarketable securitiesProperty, plant, and equipment, netDeferred tax assetsIntangible assets, netOther noncurrent assetsAccrued expenses and other current liabilitiesAccounts payableDeferred revenueLong-term debtOther noncurrent liabilitiesFinance lease liabilitiesDeferred revenueRetained earningsAdditional paid-in capitalCommon stock - Common StockCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury Stock, at cost; 28.2 shares in 2024 and 25.5 shares in 2023Accumulated other comprehensive lossCurrent liabilitiesCurrent liabilities$3.94 BAccrued expenses and other current liabilitiesAccrued expenses and other current liabilities$2.53 BAccounts payableAccounts payable$789.50 MLiabilitiesLiabilities$8.41 BDeferred revenueDeferred revenue$627.70 MCurrent assetsCurrent assets$18.66 BMarketable securitiesMarketable securities$6.52 BLong-term debtLong-term debt$1.98 BNon-current liabilitiesNon-current liabilities$4.46 BAssetsAssets$37.76 BAccounts receivable, netAccounts receivable, net$6.21 BOther noncurrent liabilitiesOther noncurrent liabilities$1.57 BEquityEquity$29.35 BFinance lease liabilitiesFinance lease liabilities$720.00 MInventoriesInventories$3.09 BDeferred revenueDeferred revenue$185.70 MCash and cash equivalentsCash and cash equivalents$2.49 BGross equity (calculated)Gross equity(calculated)$44.53 BPrepaid expenses and other current assetsPrepaid expenses and other current assets$349.20 MNon-current assetsNon-current assets$19.10 BMarketable securitiesMarketable securities$8.90 BRetained earningsRetained earnings$31.67 BProperty, plant, and equipment, netProperty, plant, and equipment, net$4.60 BDeferred tax assetsDeferred tax assets$3.31 BIntangible assets, netIntangible assets, net$1.15 BOther noncurrent assetsOther noncurrent assets$1.14 BAdditional paid-in capitalAdditional paid-in capital$12.86 BCommon stock - Common StockCommon stock - Common Stock$100.00 KTreasury Stock, at cost; 28.2 shares in 2024 and 25.5 shares in 2023Treasury Stock−$15.17 BAccumulated other comprehensive lossAccumulated other comprehensive loss−$7.90 M
Chart details

REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Annual Balance Sheet

Balance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.

Assets
37,759,400,000 US dollars
Current assets
18,660,900,000 US dollars
Non-current assets
19,098,500,000 US dollars
Liabilities
8,405,800,000 US dollars
Current liabilities
3,944,300,000 US dollars
Non-current liabilities
4,461,500,000 US dollars
Equity
29,353,600,000 US dollars
Marketable securities
6,524,300,000 US dollars
Accounts receivable, net
6,211,900,000 US dollars
Inventories
3,087,300,000 US dollars
Cash and cash equivalents
2,488,200,000 US dollars
Prepaid expenses and other current assets
349,200,000 US dollars
Marketable securities
8,900,100,000 US dollars
Property, plant, and equipment, net
4,599,700,000 US dollars
Deferred tax assets
3,314,100,000 US dollars
Intangible assets, net
1,148,600,000 US dollars
Other noncurrent assets
1,136,000,000 US dollars
Accrued expenses and other current liabilities
2,527,100,000 US dollars
Accounts payable
789,500,000 US dollars
Deferred revenue
627,700,000 US dollars
Long-term debt
1,984,400,000 US dollars
Other noncurrent liabilities
1,571,400,000 US dollars
Finance lease liabilities
720,000,000 US dollars
Deferred revenue
185,700,000 US dollars
Retained earnings
31,672,900,000 US dollars
Additional paid-in capital
12,855,900,000 US dollars
Common stock - Common Stock
100,000 US dollars
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none
0 US dollars
Common stock - Class A Stock
0 US dollars
Treasury Stock, at cost; 28.2 shares in 2024 and 25.5 shares in 2023
negative 15,167,400,000 US dollars
Accumulated other comprehensive loss
negative 7,900,000 US dollars
Gross equity (calculated)
44,528,900,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Annual Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!